Niu Yue, Han Xinwei, Xiao Huiying, Miao Ruolan, Ouyang Gege, Wang Qian, Wei Daimin
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, Shandong, China (Niu, Han, Xiao, Miao, Ouyang, and Wei).
National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Shandong University, Jinan, Shandong, China (Niu, Han, Xiao, Miao, Ouyang, and Wei).
AJOG Glob Rep. 2025 Feb 22;5(2):100461. doi: 10.1016/j.xagr.2025.100461. eCollection 2025 May.
Both antimüllerian hormone and body mass index are associated with the pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization.
This study aimed to explore the effect of different combinations of antimüllerian hormone and body mass index on pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization.
This was a post hoc secondary analysis of a multicenter randomized trial. A total of 625 women from 1 center with antimüllerian hormone levels measured before in vitro fertilization treatment were classified into 6 groups: group A (normal weight and low antimüllerian hormone group), group B (normal weight and intermediate antimüllerian hormone group), group C (normal weight and high antimüllerian hormone group), group D (overweight/obese and low antimüllerian hormone group), group E (overweight/obese and intermediate antimüllerian hormone group), and group F (overweight/obese and high antimüllerian hormone group).
After adjustment via multivariate logistic regression, the overweight/obese and high antimüllerian hormone group (group F) had a higher risk of clinical pregnancy miscarriage (adjusted odds ratio, 3.30; 95% confidence interval, 1.35-8.07) than the normal weight and intermediate antimüllerian hormone group (group B). Both the normal weight and high antimüllerian hormone group (group C; adjusted odds ratio, 3.74; 95% confidence interval, 1.06-13.24) and the overweight/obese and high antimüllerian hormone group (group F; adjusted odds ratio, 3.61; 95% confidence interval, 1.05-12.38) had higher risks of ovarian hyperstimulation syndrome than the normal weight and intermediate antimüllerian hormone group (group B).
In women with polycystic ovary syndrome, high serum antimüllerian hormone levels were associated with an increased risk of clinical pregnancy miscarriage in women who were overweight/obese but not in those with normal weight.
抗苗勒管激素和体重指数均与接受体外受精的多囊卵巢综合征女性的妊娠结局相关。
本研究旨在探讨抗苗勒管激素和体重指数的不同组合对接受体外受精的多囊卵巢综合征女性妊娠结局的影响。
这是一项对多中心随机试验的事后二次分析。来自1个中心的625名在体外受精治疗前测量了抗苗勒管激素水平的女性被分为6组:A组(体重正常且抗苗勒管激素水平低)、B组(体重正常且抗苗勒管激素水平中等)、C组(体重正常且抗苗勒管激素水平高)、D组(超重/肥胖且抗苗勒管激素水平低)、E组(超重/肥胖且抗苗勒管激素水平中等)和F组(超重/肥胖且抗苗勒管激素水平高)。
经多因素逻辑回归调整后,超重/肥胖且抗苗勒管激素水平高的组(F组)临床妊娠流产风险高于体重正常且抗苗勒管激素水平中等的组(B组)(调整后的优势比为3.30;95%置信区间为1.35 - 8.07)。体重正常且抗苗勒管激素水平高的组(C组;调整后的优势比为3.74;95%置信区间为1.06 - 13.24)和超重/肥胖且抗苗勒管激素水平高的组(F组;调整后的优势比为3.61;95%置信区间为1.05 - 12.38)卵巢过度刺激综合征风险均高于体重正常且抗苗勒管激素水平中等的组(B组)。
在多囊卵巢综合征女性中,如果超重/肥胖,血清抗苗勒管激素水平高与临床妊娠流产风险增加相关,而体重正常者则不然。